MALDI imaging as a specific diagnostic tool for routine cervical cytology specimens

Area of Science:

• Gynecologic Oncology
• Proteomics
• Medical Diagnostics

Background:

• Cervical squamous cell carcinoma (SCC) is a major global health concern for women.
• High-risk human papillomavirus (HR-HPV) infection is the primary cause of SCC, LSIL, and HSIL.
• Current HR-HPV DNA testing helps triage low-grade abnormalities, but many HR-HPV-positive lesions do not progress to invasive cancer.

Purpose of the Study:

• To evaluate Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) as a tool for stratifying cervical cytology samples.
• To assess the ability of MALDI-IMS to differentiate between normal/low-grade (Pap I-II) and high-grade (Pap IIID or higher) cervical lesions.

Main Methods:

• Analysis of 18 Pap IIID or higher samples and 14 Pap I-II (WNL) samples using MALDI-IMS.
• Application of a genetic algorithm for automated classification of mass spectrometry spectra.
• Cross-validation to assess the accuracy of the classification model.

Main Results:

• The MALDI-IMS approach achieved an overall cross-validation accuracy of 83.7%.
• Sensitivity for detecting Pap IIID or higher (abnormal) samples was 88.9%.
• Sensitivity for detecting Pap I-II (normal/WNL) samples was 78.6%.

Conclusions:

• MALDI-IMS offers an unbiased and automated method for classifying cervical cytology samples.
• This proteomic-based approach shows potential for improving the stratification of cervical Pap smears.
• MALDI-IMS could aid in identifying patients at higher risk for significant cervical disease, optimizing clinical management.